Law & Regulation
Topo.ai and Resolver Partner to Provide Complete End-to-end Threat Protection
Topo.ai, provider of the security industry’s most flexible common operating picture, along with Resolver, the leading provider of risk intelligence,…
Topo.ai, provider of the security industry’s most flexible common operating picture, along with Resolver, the leading provider of risk intelligence, announced a formal partnership to support the physical security community. This partnership integrates Resolver’s newly launched Threat Protection solution, with the TopoONE platform. Customers can analyze threat and incident data to understand real-time impact to a range of assets within TopoONE.
“Partnering with Resolver provides our customers with an intuitive way to prioritize and action threats and avoid potential incidents,” says Alex Bagwell, CRO at Topo.ai. “Using the TopoOne platform, combined with Resolver’s Risk Intelligence platform, customers can streamline corporate security, IT, risk, and compliance processes to make highly informed business decisions. The ability to quickly identify and geolocate critical risk and have insights into them delivered in real-time via the TopoOne platform is extremely important to our customers. This partnership enables our partners to further track risk and manage severe to low-risk events from identification through to resolution, making organizations and their customers safer.”
Recommended AI News: Cyberattacks Are Now the Top Cause of Data Loss, Databarracks Research Reveals
Once a risk or emerging threat is identified, TopoONE seamlessly creates cases in Resolver’s market leading Incident Management or newly launched Threat Protection applications. These cases can then be prioritized, analyzed and actioned, with summary reports and data-feeding situation reports. Additionally, there is the seamless ability to integrate within communication channels such as Salesforce, Slack, Microsoft Teams, email, and more, to deliver best-in-class threat management. The bi-directional partnership updates case status and additional incidents into TopoONE for a fully updated and centralized view of all risks. The partnership continues to highlight the need for cooperation between security technology vendors across different platforms.
“Security teams recognize the importance of detecting and responding to threats, external and internal,” says Artem Sherman, Product Manager at Resolver. “Teams often have multiple systems and sources in place and need a way to bring them all together into a powerful platform that enables fast and effective triage, investigation, cross-functional collaboration, and response. Security leaders want to avoid disparate and manual processes, and need the ability to understand trends, gain insights, and mitigate future exposure. Resolver’s Threat Management offering leverages years of industry knowledge and experience to serve those needs and advance our risk intelligence vision,” Sherman explains.
Recommended AI News: Bain & Company, the Inventor of NPS, Launches NPSx, a new Digital Venture
[To share your insights with us, please write to sghosh@martechseries.com]
The post Topo.ai and Resolver Partner to Provide Complete End-to-end Threat Protection appeared first on AiThority.
research nps-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
-
Psychedelics4 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID